133 related articles for article (PubMed ID: 6726955)
1. The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma.
Jayachandran S; Unni Mooppan MM; Wax SH; Kim H
J Urol; 1984 Jul; 132(1):21-3. PubMed ID: 6726955
[TBL] [Abstract][Full Text] [Related]
2. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of urinary fibrinogen degradation products in bladder carcinoma.
Alsabti EA
Eur Surg Res; 1979; 11(3):185-90. PubMed ID: 510327
[TBL] [Abstract][Full Text] [Related]
4. A correlative study on urinary cytology and FDP with cystoscopy and pathology in the urinary bladder cancers.
Tanahashi T; Matsumura Y; Ohmori H; Tanaka T
Acta Med Okayama; 1978 Jun; 32(2):139-46. PubMed ID: 150199
[TBL] [Abstract][Full Text] [Related]
5. Urinary fibrin/fibrinogen degradation products in transitional cell carcinoma of the bladder.
Ewing R; Tate GM; Hetherington JW
Br J Urol; 1987 Jan; 59(1):53-8. PubMed ID: 3828688
[TBL] [Abstract][Full Text] [Related]
6. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
7. [Urine cytology and urine markers. Significance for clinical practice].
Tritschler S; Zaak D; Knuechel R; Stief CG
Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of urinary cytology in the detection of recurrent bladder tumours.
Baltaci S; Süzer O; Ozer G; Bedük Y; Göğüş O
Int Urol Nephrol; 1996; 28(5):649-53. PubMed ID: 9061424
[TBL] [Abstract][Full Text] [Related]
9. Further study of fibrinogen degradation products in bladder cancer detection.
Wajsman Z; Williams PD; Greco J; Murphy GP
Urology; 1978 Dec; 12(6):659-61. PubMed ID: 741544
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma.
Meuleman EJ; Delaere KP
Br J Urol; 1988 Aug; 62(2):150-3. PubMed ID: 3408887
[TBL] [Abstract][Full Text] [Related]
11. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
[TBL] [Abstract][Full Text] [Related]
12. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
13. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
14. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
15. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
17. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biological markers in bladder cancer.
Wajsman Z; Merrin CE; Chu TM; Moore RH; Murphy GP
J Urol; 1975 Dec; 114(6):879-93. PubMed ID: 1195467
[TBL] [Abstract][Full Text] [Related]
19. [Urinary cytology in cases of bladder cancer: a critical evaluation].
Rathert P
Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
[TBL] [Abstract][Full Text] [Related]
20. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]